Mineralys Therapeutics, Inc. (MLYS)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Mineralys Therapeutics’ earnings missed expectations as its third fiscal quarter of 2026 results, reported November 4, 2026, showed EPS of -$0.64 trailing the -$0.55 estimate by -$0.09, based on preliminary results. The quarter’s net loss widened, with net income down 55.2% year over year to roughly -$57.3 million versus -$36.9 million a year ago, and operating income coming in around -$60.1 million. EPS was down 23.1% from -$0.52 a year ago, consistent with the larger net loss for this clinical-stage biotechnology business focused on its lorundrostat program. Cash usage also remained significant, with negative operating cash flow of about -$43.1 million. For the next period, consensus calls for EPS of -$0.65 on revenue of $1.5 million.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops medicines for diseases driven by abnormally elevated aldosterone. In qualitative terms, it is a clinical-stage drug developer rather than a commercial biopharma business, with its work centered on cardiorenal disorders tied to excess aldosterone.
Today's Snapshot
MLYS closed 4.8% below yesterday's close, in line with a weaker sector. The day ended with MLYS within 0.2% of its 52-week low of 13.75. Mineralys reported its blood-pressure drug sustained reductions ahead of an FDA decision.
Trading Volume
Below 10d avg (1.8M)
1.3M
vs S&P 500 Today
Strong Underperformance
-4.57%
Updated: November 18, 2026 at 21:10 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$15.38 - $26.30Sell
- RSI (14)27.40Buy
- Stochastic %K (14, 3, 3)1.20Buy
- MACD Level (12, 26)-2.11Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.